These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 29634241)

  • 1. Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes.
    Cox G; Ejim L; Stogios PJ; Koteva K; Bordeleau E; Evdokimova E; Sieron AO; Savchenko A; Serio AW; Krause KM; Wright GD
    ACS Infect Dis; 2018 Jun; 4(6):980-987. PubMed ID: 29634241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions.
    Castanheira M; Davis AP; Serio AW; Krause KM; Mendes RE
    Diagn Microbiol Infect Dis; 2019 May; 94(1):73-77. PubMed ID: 30661726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and phylogenetic analyses of resistance to next-generation aminoglycosides conferred by AAC(2') enzymes.
    Bassenden AV; Dumalo L; Park J; Blanchet J; Maiti K; Arya DP; Berghuis AM
    Sci Rep; 2021 Jun; 11(1):11614. PubMed ID: 34078922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.
    Almaghrabi R; Clancy CJ; Doi Y; Hao B; Chen L; Shields RK; Press EG; Iovine NM; Townsend BM; Wagener MM; Kreiswirth B; Nguyen MH
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4443-51. PubMed ID: 24867988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms.
    Castanheira M; Deshpande LM; Woosley LN; Serio AW; Krause KM; Flamm RK
    J Antimicrob Chemother; 2018 Dec; 73(12):3346-3354. PubMed ID: 30219857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.
    Galani I; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Souli M;
    BMC Infect Dis; 2019 Feb; 19(1):167. PubMed ID: 30770727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activity of plazomicin and older aminoglyosides against Enterobacterales isolates; prevalence of aminoglycoside modifying enzymes and 16S rRNA methyltransferases.
    Gür D; Hasdemir U; Çakar A; Çavuşoğlu İ; Çelik T; Aksu B;
    Diagn Microbiol Infect Dis; 2020 Aug; 97(4):115092. PubMed ID: 32569921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the 1- N-(4-Amino-2 S-hydroxybutyryl) and 6'- N-(2-Hydroxyethyl) Substituents on Ribosomal Selectivity, Cochleotoxicity, and Antibacterial Activity in the Sisomicin Class of Aminoglycoside Antibiotics.
    Sonousi A; Sarpe VA; Brilkova M; Schacht J; Vasella A; Böttger EC; Crich D
    ACS Infect Dis; 2018 Jul; 4(7):1114-1120. PubMed ID: 29708331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
    Zhanel GG; Lawson CD; Zelenitsky S; Findlay B; Schweizer F; Adam H; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Expert Rev Anti Infect Ther; 2012 Apr; 10(4):459-73. PubMed ID: 22512755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: potency of plazomicin alone and in combination with other agents.
    López Díaz MC; Ríos E; Rodríguez-Avial I; Simaluiza RJ; Picazo JJ; Culebras E
    Int J Antimicrob Agents; 2017 Aug; 50(2):191-196. PubMed ID: 28577932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular identification of aminoglycoside-modifying enzymes in clinical isolates of Escherichia coli resistant to amoxicillin/clavulanic acid isolated in Spain.
    Fernández-Martínez M; Miró E; Ortega A; Bou G; González-López JJ; Oliver A; Pascual A; Cercenado E; Oteo J; Martínez-Martínez L; Navarro F;
    Int J Antimicrob Agents; 2015 Aug; 46(2):157-63. PubMed ID: 26022930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plazomicin Activity against 346 Extended-Spectrum-β-Lactamase/AmpC-Producing Escherichia coli Urinary Isolates in Relation to Aminoglycoside-Modifying Enzymes.
    López-Diaz MD; Culebras E; Rodríguez-Avial I; Rios E; Viñuela-Prieto JM; Picazo JJ; Rodríguez-Avial C
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expected plazomicin susceptibility in India based on the prevailing aminoglycoside resistance mechanisms in Gram-negative organisms derived from whole-genome sequencing.
    Pragasam AK; Jennifer SL; Solaimalai D; Muthuirulandi Sethuvel DP; Rachel T; Elangovan D; Vasudevan K; Gunasekaran K; Veeraraghavan B
    Indian J Med Microbiol; 2020; 38(3 & 4):313-318. PubMed ID: 33154241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
    Eljaaly K; Alharbi A; Alshehri S; Ortwine JK; Pogue JM
    Drugs; 2019 Feb; 79(3):243-269. PubMed ID: 30723876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plazomicin: an investigational therapy for the treatment of urinary tract infections.
    Karaiskos I; Souli M; Giamarellou H
    Expert Opin Investig Drugs; 2015; 24(11):1501-11. PubMed ID: 26419762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis for plazomicin antibiotic action and resistance.
    Golkar T; Bassenden AV; Maiti K; Arya DP; Schmeing TM; Berghuis AM
    Commun Biol; 2021 Jun; 4(1):729. PubMed ID: 34117352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel aminoglycoside 2''-phosphotransferase identified in a gram-negative pathogen.
    Toth M; Frase H; Antunes NT; Vakulenko SB
    Antimicrob Agents Chemother; 2013 Jan; 57(1):452-7. PubMed ID: 23129050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of vertilmicin to modifications by three types of recombinant aminoglycoside-modifying enzymes.
    Yuan M; Han H; Li CR; Yang XY; Li GQ; Cen S; Kang XX; Si SY; Jiang JD; You XF
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3950-3. PubMed ID: 21646489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae.
    Thwaites M; Hall D; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.
    Denervaud-Tendon V; Poirel L; Connolly LE; Krause KM; Nordmann P
    J Antimicrob Chemother; 2017 Oct; 72(10):2787-2791. PubMed ID: 29091226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.